<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39214">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595892</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-01910</org_study_id>
    <secondary_id>NCI-2015-01910</secondary_id>
    <secondary_id>9944</secondary_id>
    <secondary_id>9944</secondary_id>
    <secondary_id>P30CA006516</secondary_id>
    <secondary_id>UM1CA186709</secondary_id>
    <nct_id>NCT02595892</nct_id>
  </id_info>
  <brief_title>Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer</brief_title>
  <official_title>Phase 2 Study of VX-970 (NSC# 780162) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well Ataxia-telangiectasia and Rad3-related [ATR]
      kinase inhibitor VX-970 (VX-970) and gemcitabine hydrochloride work compared to standard
      treatment with gemcitabine hydrochloride alone in treating patients with ovarian, primary
      peritoneal, or fallopian tube cancer that has come back after a period of improvement
      (recurrent). ATR kinase inhibitor VX-970 may stop the growth of tumor cells by blocking an
      enzyme needed for cell growth, and may also help gemcitabine hydrochloride work better.
      Gemcitabine hydrochloride is a drug used in chemotherapy that works to stop the growth of
      tumor cells by blocking cells from growing and repairing themselves, causing them to die. It
      is not yet known whether adding ATR kinase inhibitor VX-970 to standard treatment with
      gemcitabine hydrochloride is more effective than gemcitabine hydrochloride alone in treating
      patients with ovarian, primary peritoneal, or fallopian tube cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess and compare progression free survival (PFS) between gemcitabine (gemcitabine
      hydrochloride)/VX-970 and gemcitabine alone arms.

      SECONDARY OBJECTIVES:

      I. Determine and compare overall response rate (ORR) by Response Evaluation Criteria in
      Solid Tumors (RECIST) between gemcitabine/VX-970 and gemcitabine alone arms.

      II. Determine and compare the safety profile of gemcitabine/VX-970 and gemcitabine alone
      regimens.

      III. Assess and compare PFS at 6 months between gemcitabine/VX-970 and gemcitabine alone
      arms.

      IV. Determine and compare the clinical benefit rate (CBR) between gemcitabine/VX-970 and
      gemcitabine alone arms.

      V. Determine and compare the duration of response (DOR) between gemcitabine/VX-970 and
      gemcitabine alone arms.

      VI. Determine and compare cancer antigen (CA)125 reduction by &gt;= 50% between
      gemcitabine/VX-970 and gemcitabine alone arms.

      VII. Determine and compare overall survival (OS) between gemcitabine/VX-970 and gemcitabine
      alone arms.

      VIII. Determine the ORR for subjects in the gemcitabine alone arm who cross over to the
      gemcitabine/VX-970 arm.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days
      1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable
      toxicity. Patients experiencing disease progression may crossover to Arm II.

      ARM II: Patients receive gemcitabine hydrochloride as in Arm I and ATR kinase inhibitor
      VX-970 IV over 60-90 minutes on days 2 and 9. Courses repeat every 21 days in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days, every 3 months for
      1 year, and then every 6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Number of days from the day the subject received the first dose of protocol therapy to the date of documented progressive disease by RECIST version 1.1 or death (regardless of cause), assessed up to 3 years</time_frame>
    <description>PFS will be summarized using Kaplan-Meier analyses and compared between the two arms using the logrank test. PFS will additionally be analyzed using a Cox Proportional Hazards Model, including the stratification factor, and will be used to estimate the hazard ratio of the gemcitabine hydrochloride/ATR kinase inhibitor VX-970 arm relative to the gemcitabine hydrochloride alone arm and the associated 90% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CBR, defined as the percentage of subjects achieving a response rating of stable disease &gt;= 4 months, PR, or CR</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Subject demographic and baseline characteristics will be summarized by mean, standard deviation, median, minimum, and maximum for continuous variables; and by counts and percentages for categorical variables. Summaries will be provided separately for each treatment group. Treatment group comparisons in CBR will be evaluated using logistic regression and expressed as odds ratios with associated 90% confidence intervals. In the event that rates are low, comparisons will be based on Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CA125 serum levels</measure>
    <time_frame>Baseline to up to 30 days after last dose of study treatment</time_frame>
    <description>Subject demographic and baseline characteristics will be summarized by mean, standard deviation, median, minimum, and maximum for continuous variables; and by counts and percentages for categorical variables. Summaries will be provided separately for each treatment group. Percent of subjects with at least 50% reduction in CA-125 will be evaluated and presented with 95% confidence intervals and compared across the two groups using z-test for independent proportions. Treatment group comparisons in CA-125 50% reduction will be evaluated using logistic regression and expressed as odds ratios with</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Informational summaries and Kaplan Meier plots, without formal statistical comparisons, will be produced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</measure>
    <time_frame>Up to 30 days after last dose of study treatment</time_frame>
    <description>The following minimum data summaries will be presented by treatment arm for safety assessments: treatment-emergent adverse events of any CTCAE grade - summarized by system organ class and CTCAE grade, serious adverse events, deaths summarized by primary cause, and laboratory parameters (hematology and chemistry), vital signs, electrocardiogram data and concomitant medications will be summarized appropriately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR after crossover following disease progression with single agent gemcitabine hydrochloride</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Subject demographic and baseline characteristics will be summarized by mean, standard deviation, median, minimum, and maximum for continuous variables; and by counts and percentages for categorical variables. Summaries will be provided separately for each treatment group. Treatment group comparisons in ORR will be evaluated using logistic regression and expressed as odds ratios with associated 90% confidence intervals. In the event that rates are low, comparisons will be based on Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR, defined as the percentage of subjects achieving a response rating of complete response (CR) or partial response (PR) by RECIST guideline v1.1</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Subject demographic and baseline characteristics will be summarized by mean, standard deviation, median, minimum, and maximum for continuous variables; and by counts and percentages for categorical variables. Summaries will be provided separately for each treatment group. Treatment group comparisons in ORR will be evaluated using logistic regression and expressed as odds ratios with associated 90% confidence intervals. In the event that rates are low, comparisons will be based on Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Number of days from the day the subject received the first dose of protocol therapy until date of death (regardless of cause), assessed up to 3 years</time_frame>
    <description>OS will be summarized using Kaplan-Meier analyses and compared between the two arms using the logrank test. OS will additionally be analyzed using a Cox proportional hazards model, including the stratification factor, and will be used to estimate the hazard ratio of the gemcitabine hydrochloride/ATR kinase inhibitor VX-970 arm relative to the gemcitabine hydrochloride alone arm and the associated 90% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Number of days from the day the subject received the first dose of protocol therapy to the date of documented progressive disease by RECIST version 1.1 or death (regardless of cause), assessed at 6 months</time_frame>
    <description>PFS will be summarized using Kaplan-Meier analyses and compared between the two arms using the logrank test. PFS will additionally be analyzed using a Cox proportional hazards model, including the stratification factor, and will be used to estimate the hazard ratio of the gemcitabine hydrochloride/ATR kinase inhibitor VX-970 arm relative to the gemcitabine hydrochloride alone arm and the associated 90% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Ovarian Serous Tumor</condition>
  <condition>Recurrent Fallopian Tube Carcinoma</condition>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <condition>Recurrent Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (gemcitabine hydrochloride)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (gemcitabine, ATR kinase inhibitor VX-970)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride as in Arm I and ATR kinase inhibitor VX-970 IV over 60-90 minutes on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR Kinase Inhibitor VX-970</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (gemcitabine, ATR kinase inhibitor VX-970)</arm_group_label>
    <other_name>VX-970</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (gemcitabine hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (gemcitabine, ATR kinase inhibitor VX-970)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (gemcitabine hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (gemcitabine, ATR kinase inhibitor VX-970)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed high grade serous ovarian or primary
             peritoneal or fallopian tube cancer; platinum resistant disease is defined as
             progression within 6 months after last platinum regimen

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as &gt;= 20 mm (&gt;= 2 cm) with
             conventional techniques or as &gt;= 10 mm (&gt;= 1 cm) with spiral computed tomography (CT)
             scan, magnetic resonance imaging (MRI), or calipers by clinical exam; measurable
             disease by RECIST version (v)1.1 with at least one measurable target lesion

          -  Prior therapy: No line limit but no more than 1 prior regimens in the platinum
             resistant setting; no prior treatment targeting the ATR/checkpoint kinase 1 (CHK1)
             pathway and no prior gemcitabine as single agent; hormonal therapies and
             antiangiogenic therapies (as single agents) do not count as lines; poly (adenosine
             diphosphate [ADP]-ribose) polymerases (PARP)-inhibitors count as line of therapy;
             prior carboplatin/gemcitabine is allowed provided that there was no disease
             progression within 12 months after completion of the carboplatin/gemcitabine regimen;
             subjects may begin protocol treatment at least 4 weeks or 5 half-lives, whichever is
             shorter, after their last dose of chemotherapy or hormonal therapy, assuming they are
             otherwise eligible

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky &gt;=
             70%)

          -  Life expectancy of greater than 6 months

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2.5 Ã— institutional upper limit of normal

          -  Creatinine within normal institutional limits OR creatinine clearance &gt;= 60
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

          -  Availability of a formalin-fixed, paraffin-embedded (FFPE) tumor specimen with
             adequate tumor tissue (either one paraffin embedded tissue block OR 10 5-micron
             unstained slides from the block on regular [non-plus] slides and 1 hematoxylin and
             eosin [H&amp;E] slide)

          -  All acute, clinically significant treatment-related toxicity from prior therapy,
             except for alopecia, must have resolved to grade =&lt; 1 prior to study entry

          -  Patients with symptomatic uncontrolled brain metastases are excluded; a scan to
             confirm the absence of brain metastases is not required

          -  At least 4 weeks since major surgery or radiation therapy

          -  Women of child-bearing potential must agree to use adequate contraception (hormonal
             or barrier method of birth control; abstinence) prior to study entry, for the
             duration of study participation, and 6 months after completion of study; should a
             woman become pregnant or suspect she is pregnant while she or her partner is
             participating in this study, she should inform her treating physician immediately

          -  No known hypersensitivity or contraindication to the components of study treatment
             (VX-970, gemcitabine)

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients with primary platinum refractory disease, defined as progression while first
             line platinum based chemotherapy

          -  Patients who have had chemotherapy within 4 weeks or five half-lives, whichever is
             shorter, (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or
             those who have not recovered from adverse events due to agents administered more than
             4 weeks earlier

          -  Patients who have had radiotherapy within 4 weeks

          -  Patients who are receiving any other investigational agents

          -  Patients with known brain metastases should be excluded from this clinical trial

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to VX-970 or gemcitabine

          -  Concomitant administration with strong inhibitors or inducers of cytochrome P450,
             family 3, subfamily A, polypeptide 4 (CYP3A4) should be avoided; it is important to
             regularly consult a frequently-updated medical reference for a list of drugs to avoid
             or minimize use of; patients receiving any medications or substances that are
             inhibitors or inducers of cytochrome P450 3A (CYP3A4 enzyme) are ineligible; as part
             of the enrollment/informed consent procedures, the patient will be counseled on the
             risk of interactions with other agents, and what to do if new medications need to be
             prescribed or if the patient is considering a new over-the-counter medicine or herbal
             product

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with VX-970 and/or gemcitabine

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible; appropriate studies will be undertaken in patients receiving
             combination antiretroviral therapy when indicated
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panagiotis Konstantinopoulos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber - Harvard Cancer Center LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael T. McHale</last_name>
      <phone>858-822-5354</phone>
      <email>cancercto@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Michael T. McHale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael T. McHale</last_name>
      <phone>858-822-5354</phone>
      <email>cancercto@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Michael T. McHale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber - Harvard Cancer Center LAO</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panagiotis A. Konstantinopoulos</last_name>
      <phone>617-632-5269</phone>
      <email>Panagiotis_konstantinopoulos@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Panagiotis A. Konstantinopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panagiotis A. Konstantinopoulos</last_name>
      <phone>877-442-3324</phone>
    </contact>
    <investigator>
      <last_name>Panagiotis A. Konstantinopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander B. Olawaiye</last_name>
      <phone>412-647-2811</phone>
    </contact>
    <investigator>
      <last_name>Alexander B. Olawaiye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta A. Crispens</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Marta A. Crispens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda R. Duska</last_name>
      <phone>434-243-6322</phone>
      <email>JME3D@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda R. Duska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>November 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
